BACKGROUND: There is little data on contraceptive effectiveness or use patterns from sub-Saharan Africa. STUDY DESIGN: We analyzed data from women at risk of pregnancy (n=4905) in the Methods for Improving Reproductive Health in Africa trial of the diaphragm for HIV prevention. We described reported contraceptive method use and calculated rates of pregnancy by contraceptive method. We compared time to first pregnancy by study arm (condoms or condoms plus diaphragm), and estimated a Cox proportional hazards model to identify predictors of pregnancy. RESULTS: Condoms (25.8%), injectables (25.4%) and OC (21.6%) were the most commonly used methods; long-acting method use was rare. During the trial, 51.6% of women used the same method, 27.4% switched to a more effective method and 20.9% switched to a less effective method; 21.4% of women became pregnant. Pregnancy rates by contraceptive group mirrored published estimates; frequency of study product use was not associated with pregnancy. CONCLUSION: Long-acting methods of contraception should be made available in HIV prevention trials and to women in Southern Africa.
RCT Entities:
BACKGROUND: There is little data on contraceptive effectiveness or use patterns from sub-Saharan Africa. STUDY DESIGN: We analyzed data from women at risk of pregnancy (n=4905) in the Methods for Improving Reproductive Health in Africa trial of the diaphragm for HIV prevention. We described reported contraceptive method use and calculated rates of pregnancy by contraceptive method. We compared time to first pregnancy by study arm (condoms or condoms plus diaphragm), and estimated a Cox proportional hazards model to identify predictors of pregnancy. RESULTS: Condoms (25.8%), injectables (25.4%) and OC (21.6%) were the most commonly used methods; long-acting method use was rare. During the trial, 51.6% of women used the same method, 27.4% switched to a more effective method and 20.9% switched to a less effective method; 21.4% of women became pregnant. Pregnancy rates by contraceptive group mirrored published estimates; frequency of study product use was not associated with pregnancy. CONCLUSION: Long-acting methods of contraception should be made available in HIV prevention trials and to women in Southern Africa.
Authors: Carolyne A Akello; Katherine E Bunge; Clemensia Nakabiito; Brenda G Mirembe; Mary Glenn Fowler; Anupam Mishra; Jeanne Marrazzo; Zvavahera M Chirenje; Connie Celum; Jennifer E Balkus Journal: J Womens Health (Larchmt) Date: 2017-02-17 Impact factor: 2.681
Authors: Maricianah Onono; Kavita Nanda; Kate B Heller; Doug Taylor; Irina Yacobson; Renee Heffron; Margaret Phiri Kasaro; Cheryl E Louw; Zelda Nhlabasti; Thesla Palanee-Phillips; Jenni Smit; Imelda Wakhungu; Peter B Gichangi; Nelly R Mugo; Charles Morrison; Jared M Baeten Journal: Contracept X Date: 2020-05-28
Authors: Rena C Patel; Maricianah Onono; Monica Gandhi; Cinthia Blat; Jill Hagey; Starley B Shade; Eric Vittinghoff; Elizabeth A Bukusi; Sara J Newmann; Craig R Cohen Journal: Lancet HIV Date: 2015-10-22 Impact factor: 12.767